WO1984000875A1 - Acylguanidines - Google Patents

Acylguanidines Download PDF

Info

Publication number
WO1984000875A1
WO1984000875A1 PCT/US1983/001286 US8301286W WO8400875A1 WO 1984000875 A1 WO1984000875 A1 WO 1984000875A1 US 8301286 W US8301286 W US 8301286W WO 8400875 A1 WO8400875 A1 WO 8400875A1
Authority
WO
WIPO (PCT)
Prior art keywords
guanidine
compound
phenyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/US1983/001286
Other languages
English (en)
Inventor
William Lyon Studt
Stuart Alan Dodson
Harry Karl Zimmerman
James Lee Barnes
Original Assignee
Rorer Int Overseas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rorer Int Overseas filed Critical Rorer Int Overseas
Publication of WO1984000875A1 publication Critical patent/WO1984000875A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/64—Acyl halides
    • C07C57/76—Acyl halides containing halogen outside the carbonyl halide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Definitions

  • This invention relates to aralkyl- and aralkenyl- acyl, and thioacyl, guanidines and to their use in treating mammalian and avian species afflicted with protozoal infections or with gastrointestinal or cardiovascular disorders.
  • Amidines and related compounds such as guanidines and amidinoureas, are known to exhibit certain physiological activity in mammalian species, including antihypertensive action.
  • Exemplary antihypertensive aralkylacetylguanidines are disclosed in U.S. Pat. Nos: 3,632,645; 3,634,508; 3,822,262; and, 4,318,915.
  • Phenylamidinoureas have also been reported as possessing antisecretory, antispasmodic, antiulcerogenic, anesthetic, antidiarrheal and antihypertensive activity in a series of recent patents and publications. See: Arzneistoff Anlagen, (Drug Research) 28 (II), 1443-1480 (1978); and U.S. Patent Nos: 4,025,652; 4,058,557; 4,060,635; 4,088,785; 4,115,564; 4,115,647; 4,117,165; 4,147,804; 4,150,154; 4,169,115; 4,178,387; 4,204,000; and 4,220,658. It has been found that a class of aralkyl and aralkenyl acyl guanidines capable of tautomerism possess pharmacological activity including antiprotozoal activity.
  • R 1 is phenalkyl, substituted phenalkyl, phenalkenyl, substituted phenalkenyl, or a phenyl substituted 3 to 7 member heterocyclic ring which may include 1 to 4 hetero atoms of N, O or S, and containing a total of about 3 to 30 carbon atoms, and the N and S oxides thereof;
  • R 2 is oxygen or sulfur
  • R 3 is hydrogen or alkyl
  • R 4 and R 5 are hydrogen, alkyl, haloalkyl, cycloalkyl, aralkyl, alkenyl, aryl, alkynyl, alkoxy, acyl, aroyl, a heterocycle or a substituted heterocycle; or R 4 or R 5 together with the nitrogen to which they are attached form a 3 to 7 atom ring which may include 0 to 2 additional hetero atoms of N, O or S; or a nontoxic acid addition salt thereof.
  • Compounds according to Formula I possess useful pharmacological activity and are useful in the treatment of humans and animals suffering from physiological disorders, including gastrointestinal and cardiovascular disorders and protozoal infections including coccidiosis.
  • This invention also relates to a novel class of compounds useful in the aforesaid methods according to Formula I wherein R 1 is phenethyl, substituted phenethyl, phenalkenyl substituted phenalkenyl, or a phenyl substituted heterocyclic ring.
  • R 1 is phenyl or substituted phenyl
  • R a , R b , R c , and R d are hydrogen, lower alkyl, lower alkenyl, amino, or hydroxyl loweralkyl; or either R a and R c or R b and R d together with the carbon atoms to which they are attached form either a double bond or a 5 or 6 membered ring which may include one to four heteroatoms of N, O or S;
  • R 2 is oxygen or sulfur
  • R 3 is hydrogen or lower alkyl
  • R 4 and R 5 are hydrogen, lower alkyl, haloloweralkyl, cycloalkyl, phenalkyl, lower alkenyl, lower alkylacyl, lower alkynyl, lower alkoxy, phenyl, benzoyl, heterocycle or substituted heterocycle; or R 4 and R 5 together with the nitrogen to which they are attached form a 3 to 7 atom ring which may include 0 to 2 additional hetero atoms of N, O or S; or a nontoxic acid addition salt thereof.
  • An embodiment of this invention is a class of compounds according to Formula II wherein :
  • R a and R b form a heterocycle selected from the group consisting of pyrrole, imidizole, pyrazole, pyrrolidine, pyrroline, pyridone, pyridyl, oxazolidinyl, isoxazolyl, thiazolidinyl, pyrazolidinyl, imidazolidinyl, piperidyl, piperazinyl, morpholinyl, and thiamorpholinyl;
  • R 1 is phenyl or phenyl in which one or more phenyl hydrogens is substituted by lower alkyl, lower alkenyl, lower alkynyl, halo, nitro, cyano, sulfonyl, hydroxyl, carboxyl, lower alkanoyl, lower alkoxy, arylloweralkoxy, haloloweralkoxy, amido, amino, loweralkylamino, loweralkoxyamino, carboloweralkoxy or aralkylamino;
  • R 2 is oxygen or sulfur
  • R 3 is hydrogen or alkyl
  • R 4 and R 5 are hydrogen, lower alkyl, haloloweralkyl, lower alkenyl, cycloalkyl, benzyl, lower alkylacyl, lower alkynyl, lower alkoxy, phenyl, benzoyl, heterocycle or substituted heterocycle; or R 4 and R 5 together with the nitrogen to which they are attached form a 3 to 7 atom ring which may include 0 to 2 additional heteroatoms of N, O or S; or a nontoxic acid addition salt thereof.
  • R 1 is phenethyl, substituted phenethyl, phenalkenyl, or substituted phenalkenyl.
  • a preferred subclass of compounds according to Formulae I and II is where:
  • R 3 and R 4 are hydrogen;
  • R 5 is hydrogen, lower alkyl, haloloweralkyl, lower alkenyl, lower alkynyl, lower alkanoyl, or lower alkoxy.
  • acyl guanidine is used to encompass within its meaning “thioacyl guanidine”.
  • acyl guanidine side chain of the compounds of the present invention can be legitimately represented in any one of several tautomeric forms. In solution, one form may predominate over another depending upon the degree and location of substitution and on the nature of the solvent. The rates of conversion of one tautomer to another will depend upon the nature of the solvent, the degree of hydrogen bonding permitted, the temperature, and possibly other factors (such as pH, trace impurities and the like). To illustrate what is meant by this, a number of likely structures are here shown for just one of the compounds of this invention:
  • Alkyl means a saturated aliphatic hydrocarbon which may be either straight- or branched-chained. Preferred alkyl groups have no more than about 12 carbon atoms and may be methyl, ethyl and structural isomers of propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl.
  • Lower alkyl means an alkyl group as above, having 1 to about 6 carbon atoms.
  • Examples of lower alkyl groups are methyl, ethyl, n-propyl, isopropyl, butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl and neopentyl.
  • Cycloalkyl means an aliphatic monocyclic saturated carbocyclic group. Preferred groups have about 3 to about 6 carbon atoms, and exemplary groups include cyclopropyl, cyclopentyl and cyclohexyl.
  • Alkenyl means an unsaturated aliphatic hydrocarbon. Preferred groups have no more than about 12 carbon atoms. Exemplary groups include any structural and geometric isomers of ethenyl, propylenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, and dodecenyl or butadienyl, pentadienyl etc.
  • “Lower alkenyl” means alkenyl of about 2 to about 6 carbon atoms.
  • Preferred groups include ethylene, propylene, butylene, isobutylene, and all structural and geometrical isomers thereof.
  • Alkynyl means an unsaturated aliphatic hydrocarbon. Preferred groups have no more than about 12 carbon atoms and contain one or more triple bonds, including any structural or geometric isomers of ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, undecynyl, dodecynyl, etc. "Lower alkynyl” means alkynyl of about 2 to about 6 carbon atoms. Preferred groups include structural and geometric isomers of propargyl, butynyl, and pentynyl.
  • Aryl means phenyl and substituted phenyl.
  • Substituted phenyl means a phenyl group in which one or more of the hydrogens has been replaced by the same or different substituents including halo, lower alkyl, lower alkenyl, lower alkynyl, halo-lower alkyl, nitro, amino, acylamino, hydroxy, carboxyl, lower alkoxy, aryl lower alkoxy, acyloxy, lower alkanoyl, cyano, halo-lower alkoxy, carbolower alkoxy, amido, loweralkylamino, lower alkoxyamino, aralkylamino, or lower alkyl sulfonyl.
  • Alkyl means an alkyl group in which one or more hydrogens is substituted by an aryl group. Preferred groups are phenalkyl and substituted phenalkyl.
  • Phenalkyl means an alkyl group substituted by a phenyl group.
  • Substituted phenalkyl means a phenalkyl group in which one or more phenyl hydrogens are replaced as given above with respect to substituted phenyl.
  • Phenalkenyl is an alkenyl group substituted by phenyl.
  • Substituted phenalkenyl means a phenalkenyl group in which the phenyl group is substituted as given above with respect to substituted phenyl.
  • Heterocyclic ring or “heterocycle” means a 3, 5, 6 or 7 membered ring having 1 to 3 hetero atoms which may be nitrogen, oxygen or sulfur, including pyrrole, pyrrolidine, pyridone, heptamethyleneiminyl, pyrazole, pyridyl, pyrimidyl, pyrazolyl, imidazolyl, isoxazolyl, furyl, thienyl, oxazolyl, thiazolyl, piperidyl, morpholinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, thiamorpholinyl, azepinyl, and ethyleneiminyl.
  • “Substituted heterocycle” means a heterocycle in which one or more of the hydrogens on the ring carbons have been replaced by substituents as given above with respect to substituted phenyl
  • halo and halogen include all four halogens; namely, fluorine, chlorine, bromine and iodine.
  • the halo alkyIs, halophenyl and halo-substituted pyridyl groups include groups having more than one halo substituent which may be the same or different such as trifluoromethyl, 1-chloro-2-bromo-ethyl, chlorophenyl, and 4-chloropyridyl.
  • acyl means an organic carbonyl radical of a lower alkanoic acid.
  • Preferred acyl groups are lower alkanoyl groups such as acetyl and propionyl.
  • Aroyl means an aromatic acid radical such as benzoyl, toluoyl.
  • “Lower alkanoyl” means the acyl radical of a lower alkanoic acid such as acetyl, propionyl, butyryl, valeryl, stearoyl, and the like.
  • Alkoxy means an alkyloxy group and includes hydroxy alkyl groups. Preferred lower alkoxy groups are methoxy, ethoxy, n-propoxy, and i-propoxy, isobutoxy, n-butoxy, and t-butoxy.
  • the preferred "aryl” group is phenyl
  • the preferred "aralkyl” groups are benzyl and phenethyl.
  • the preferred "halo lower alkyl” group is trifluoromethyl.
  • the preferred "halo lower alkoxy" group is trifluoromethoxy.
  • the acyl guanidines may be prepared by the following general synthesis.
  • X may be O or S.
  • acyl chloride and thioacyl chloride starting materials are known or may be prepared according to methods known to one skilled in the art.
  • activated acyl reagents such as carbamates or thiocarbamates may be used.
  • the guanidine is preferably prepared in situ by neutralizing the guanidine acid addition salt.
  • the condensation reaction is preferably run under dry conditions. However, minute traces of water may be tolerated in the reaction mixture.
  • the reaction may be run at room temperature and may last anywhere from a few hours to a few days or the reaction temperature may be raised to that of the boiling point of the reaction media and refluxed for a few minutes to a few hours.
  • the particular compound being prepared, the solvent and reagents being used will influence the temperature, time and yield of the reaction.
  • the reaction solvent is preferably a polar aprotic solvent, such as acetone or tetrahydrofuran.
  • a 50% aqueous solution of sodium hydroxide (8.80 g), methylguanidine sulfate (13.44 g), and 100 ml of acetone, are stirred for 2-1/2 hrs at RT.
  • the resulting mixture is then treated with anhydrous sodium sulfate (6.0 g) and stirring is continued for 1 hr.
  • a solution of phenylacetyl chloride (7.73 g) in 50 ml acetone is added dropwise over a period of 1/2 hr.
  • the reaction mixture is stirred overnight at RT.
  • the reaction mixture is diluted with 100 ml of saturated aqueous sodium bicarbonate and the acetone is evaporated.
  • the mixture is diluted with 100 ml H 2 O and extracted with two 100 ml portions of methylene chloride.
  • the organic extract is dried with sodium sulfate, filtered and the filtrate evaporated in vacuo.
  • the residual solid is dissolved in methanol and the solution acidified with methanolic hydrochloric acid.
  • the acidic solution is evaporated in vacuo and the residue triturated in diethyl ether affording a tan solid which is recrystallized from acetone as a white solid, M.P. 131° C.
  • the acetone is evaporated in vacuo, and the aqueous residue diluted with 100 ml H 2 O and extracted with two 100 ml portions of methylene chloride.
  • the combined organic extracts are dried with sodium sulfate, filtered and concentrated in vacuo.
  • the concentrate is acidified with ethereal hydrochloric acid and the solvent evaporated in vacuo.
  • the residue is stirred in 200 ml of diethyl ether.
  • the resultant solid is collected, washed with diethyl ether, dried in air and recrystallized, affording 5.43 g of a white solid, M.P. 126°-128° C.
  • a mixture of a 50% aqueous solution of sodium hydroxide (8.80 g), ethylguanidine sulfate (14.98 g), and 100 ml of acetone is stirred for 2-1/2 hrs at RT.
  • the reaction mixture is treated with anhydrous sodium sulfate (6.0 g) and stirred for 1 hr.
  • a solution of 4-chlorophenylacetylchloride (9.45 g) in 50 ml acetone is added to the reaction mixture dropwise and the mixture stirred overnight.
  • the mixture is filtered, and the filtrate diluted with 100 ml of saturated aqueous sodium bicarbonate and the acetone evaporated in vacuo.
  • the aqueous mixture is diluted with 100 ml of H 2 O and extracted with two 100 ml portions of methylene chloride. The combined extracts are dried with sodium sulfate, filtered and evaporated in vacuo. The resulting solution is treated with ethereal hydrochloric acid, and the solvent evaporated in vacuo. The residue is stirred with 200 ml of diethyl ether for 1/2 hr. The diethyl-ether insoluble solid is collected and dried in air. The product is recrystallized from CH 3 CN to afford 6.03 g of white crystalline solid, M.P. 146°-147° C.
  • the acetone is evaporated in vacuo, and the aqueous residue diluted with 100 ml of H 2 O and extracted with two 100 ml portions of methylene chloride. The combined extracts are dried with sodium sulfate, filtered and concentrated in vacuo. The resulting solution is acidified with ethereal hydrochloric acid and the solvent evaporated in vacuo. The residual oil is stirred with 200 ml of diethyl ether for 2 hrs. The resulting solid is washed with diethyl ether, dried in air and recrystallized from acetone to afford 6.5 g of a white solid, M.P. 162°-163.5° C.
  • the aqueous residue is diluted with 100 ml of H 2 O and extracted with two 100 ml portions of methylene chloride. The combined extracts are dried with sodium sulfate, filtered and concentrated in vacuo. The resulting solution is acidified with ethereal hydrochloric acid and the solvent evaporated jji vacuo. The residue is stirred with 200 ml of diethyl ether and the solid collected, washed with diethyl ether and recrystallized from acetone, affording the product, M.P. 108°-110° C.
  • the residue is diluted with 100 ml H 2 O and extracted with two 100 ml portions of methylene chloride.
  • the extract is dried with sodium sulfate, filtered and concentrated in vacuo.
  • the concentrate is acidified with ethereal hydrochloric acid and the solvent evaporated in vacuo.
  • the solid is collected, washed with diethyl ether and dried in air.
  • the residual solid is recrystallized from acetone affording a white solid, M.P. 127°-128o C.
  • the resulting solid is extracted with 50 ml of boiling acetonitrile, filtered while hot, and the filtrate evaporated in vacuo.
  • the resulting white solid is extracted with hot chloroform, filtered and the filtrate evaporated to dryness.
  • the residue is recrystallized from benzene/chloroform.
  • the solvent is removed and the residue dried in vacuo.
  • the resulting material is taken up in ca 100 ml of chloroform, washed with 100 ml H 2 O and the chloroform layer separated, dried with magnesium sulfate and evaporated to dryness to afford a yellow oil.
  • the yellow oil is taken up in chloroform and the resulting solution brought to pH 2 with methanolic hydrochloric acid.
  • the solution is evaporated to dryness and the residual yellow solid crystallized to afford 4.38 g of tan crystalline solid, M.P. 225.5°-227° C.
  • the aqueous layer is extracted with methylene chloride, the combined organic extract is dried over anhydrous magnesium sulfate, filtered and concentr t d in vacuo to a yellow oil.
  • the resulting oil crystallizes on standing.
  • the crystallized solid is dissolved in hot acetonitrile, filtered and recrystallized.
  • the white solid is collected and dried in air, M.P. 166°-171° C.
  • Step II 1-(5-methyl-3-phenyl-4-isoxazoloyl)3-ethyl- guanidine
  • the aqueous residue is diluted with 100 ml H 2 O and extracted with two 100 ml portions of methylene chloride. The combined organic extract is dried, filtered and concentrated in vacuo. The residue is acidified with ethereal hydrochloric acid and evaporated in vacuo. The residue is stirred with 200 ml of diethyl ether, the solid collected and washed with diethyl ether. Recrystallization from acetonitrile affords 11.7 g of white crystalline product, M.P. 215° C.
  • acylguanidines of this invention may be readily converted to their nontoxic acid addition salts by customary methods in the art.
  • the nontoxic salts of this invention are formed from acids which are pharmacologically acceptable in the intended dosages. Such salts include those prepared from inorganic acids and organic acids.
  • Exemplary acids are hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methane sulfonic acid, benzene sulfonic acid, acetic acid, lactic acid, salicylic acid, benzoic acid, nicotinic acid, phthalic acid, stearic acid, oleic acid, abietic acid, and oxalic acid.
  • a most preferred class of acyl guanidines for use in the anti-protozoal method of this invention are the compounds of Formula III.
  • x is zero or one
  • R a , R b , R c and R may be the same or different and are hydrogen, alkyl, alkoxy, hydroxy, amino, lower alkylamino, or either R a and R b or R c and R d form a double bond or together with the carbon atoms to which they are attached form a 5 or 6 membered heterocycle;
  • R', R", R e , R f , R g are hydrogen or phenyl substituents as defined herein and at least one of R' and R" is other than hydrogen;
  • R 3 and R 4 are hydrogen or lower alkyl
  • R 5 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, halo lower alkyl, and lower alkoxy.
  • the compounds described herein possess useful anti-protozoal properties as well as anticoccidial activity in mammalian and avian species.
  • the gastric secretion test is carred out as follows: Shay rats are fasted for 4-8 hours and water is given ad lib. The rats are selected at random and separated into groups of ten. The animals are treated intraduodenally (I.D.) with the test compound or the vehicle immediately subsequent to the ligation of the stomach at the pyloric sphincter. The animals are sacrificed with chloroform at four hours post-drug-administration, the stomach removed and its contents assayed for volume, pH and total acids.
  • I.D. intraduodenally
  • Determination of antispasmolytic properties can be carried out by the procedure outlined by D. A. Brodie and S. K. Kundrats in their article entitled “Effect of Drugs on Gastric Emptying in Rats,” Fed. Proc. 24:714 (1965). Acute toxicity is calculated according to the standard Litchfield-Wilcoxon procedure.
  • Tests in animals can be carried out to show the ability of the compounds of this invention to inhibit reactions that can be correlated with antihypertensive effects in humans.
  • One such test is outlined by Jacques de Champlain, Lawrence R. Krahoff and Julius Axelrod in Circulation Research XXIII:479 (1968). This testing method is known to correlate well with antihypertensive activity in humans and is a standard test used to determine antihypertensive properties.
  • 1-(2,6-dichloro ⁇ henylacetyl)-3- ethyl guanidine possesses an optimum activity against Eimeria tenella in vitro at a concentration of 10 ⁇ g/ml, a toxicity of 100/xg/ml and a 50% lethal dose range between 82-135 mg/kg. Similar results were obtained with the 3-n- ⁇ ropyl homolog. In addition, excellent i n vivo anticoccidial activity in chickens has been found with 1-(2, 6-dichlorophenylacetyl)-3-ethyl guanidine.
  • the dosage regimen in carrying out the methods of this invention is that which ensures maximum therapeutic response until improvement is obtained, and thereafter the minimum effective level which gives relief.
  • the dosages are those that are therapeutically effective in the treatment of protozoal infections, of gastrointestinal disease conditions or symptoms, such as duodenal ulcer, peptic ulcer or diarrhea, and in the alleviation of hypertensive and arrhythmic disorders.
  • the therapeutically effective doses correspond to those dosage amounts found effective in tests using animal models which are known to correlate to human activity for each particular disorder.
  • the acyl guanidines of this invention can be normally administered orally, parenterally or rectally. Orally, they may be administered as tablets, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Parenterally, they may be administered as a salt in solution which pH is adjusted to physiologically accepted values. Aqueous solutions are preferred.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents, and preserving agents, in order to provide a pharmaceutically administrable preparation.
  • the active acyl guanidine may be administered alone or in admixture with other agents having the same or different pharmacological properties.
  • the composition may contain selected excipients, for example: inert diluents such as calcium carbonate, lactose, etc.; granulating and disintegrating agents such as maize starch, alginic acid, etc.; lubricating agents such as magnesium stearate, etc.; binding agents such as starch gelatin, etc.; suspending agents such as methylcellulose, vegetable oil, etc.; dispersing agents such as lecithin, etc.; thickening agents such as beeswax, hard paraffin, etc.; emulsifying agents such as naturally occurring gums, etc.; nonirritating excipients such as cocoa butter, polyethylene glycols, etc.
  • inert diluents such as calcium carbonate, lactose, etc.
  • granulating and disintegrating agents such as maize starch, alginic acid, etc.
  • lubricating agents such as magnesium stearate, etc.
  • binding agents such as starch gelatin, etc.
  • compositions for every 100 parts by weight of the composition, there may be present between 5 and 95 parts by weight of the active ingredient.
  • the dosage unit form will generally contain between 0.1 mg and about 500 mg of the active ingredients of this invention.
  • the preferred unit dose is between 1 mg and about 50 mg.
  • the compositions may be taken 1-8 times daily, depending on the dosage unit required.
  • a batch of homogeneous tablets was prepared, each having the following formula:
  • the following procedure is used to prepare the tablets: 1-ethyl-3-(2,6-dichlorophenylacetyl) guanidine, cellulose and 100 gm of starch are blended together dry. A paste of the remaining starch is prepared with deionized water in a steamed jacketed pot. The two components are mixed, granulated and passed through a #S screen then dried in a Fluid Bed Dryer at about 400oC and again passed through a #14 mesh screen. The composition is then formed into tablets by compressing on a Stokes Rotary Multi-Layer Tablet Press.
  • compositions of the invention are prepared by using known techniques for compounding employing either the base or a salt as the active ingredient along with nontoxic excipients chosen in accordance with the particular form and properties desired for the therapeutic composition.
  • Other therapeutic agents such as analgesics, tranquilizers, etc. may be added as desired.
  • ethylcellulose dibutylphthalate, propylene glycol, wax (white and/or carnauba), spermaceti, methylene chloride, and rectified diethyl ether.
  • the ingredients are compressed to minimum size to provide a tablet of about 310 mg.
  • the active ingredient and dicalcium phosphate are mixed thoroughly and granulated with a 7.5% solution of methylcellulose in water and passed through a #S screen and air-dried.
  • the granules are passed through a #12 screen and combined with the talc, starch and magnesium stearate with thorough mixing after which the composition is compressed into tablets.
  • the ingredients are mixed thoroughly and filled into capsules which are used for oral administration at the rate of about one every four hours. If desired, slow release forms can be provided or delayed release forms depending on choice of capsules and formulating ingredients.
  • animal feed compositions containing an antiprotozoal effective amount of a heterocyclic acyl guanidine of Formula III and a suitable feed carrier may be prepared according to methods known in the art.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Procédés de traitement de troubles physiologiques, dont les infections protozoaires chez le mammifère et l'avien, ainsi que les troubles gastro-intestinaux et cardio-vasculaires chez le mammifère, par l'administration d'une classe de composés d'aralkylguanidine, d'aralkénylacylguanidine et de thioacylguanidine, compositions pharmaceutiques contenant de tels composés pour l'administration systémique, ainsi qu'une classe de nouvelles aralkénylguanidines, de cycloalkylguanidines aryl substituées, d'acylguanidines hétérocycliques aryl substituées et de thioacylguanidines aryl substituées.
PCT/US1983/001286 1982-08-24 1983-08-23 Acylguanidines WO1984000875A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/410,958 US4544670A (en) 1982-08-24 1982-08-24 Method of treating coccidiosis with acyl guanidines

Publications (1)

Publication Number Publication Date
WO1984000875A1 true WO1984000875A1 (fr) 1984-03-15

Family

ID=23626968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1983/001286 WO1984000875A1 (fr) 1982-08-24 1983-08-23 Acylguanidines

Country Status (5)

Country Link
US (1) US4544670A (fr)
EP (1) EP0116639A4 (fr)
JP (1) JPS59501717A (fr)
AU (1) AU557648B2 (fr)
WO (1) WO1984000875A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0612723A1 (fr) * 1993-02-20 1994-08-31 Hoechst Aktiengesellschaft Benzoylguanidines substituées, procédé de leur préparation, leur utilisation comme médicament, comme inhibiteurs de l'échange cellulaire de Na+/H+ ou comme agent diagnostique et médicament les contenant
EP0639573A1 (fr) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
EP0640587A1 (fr) * 1993-08-24 1995-03-01 Hoechst Aktiengesellschaft Guanidines diacyl substitués, procédé de leur préparation, leur utilisation comme médicament ou comme agent diagnostique ainsi que médicaments les contenant
EP0666252A1 (fr) * 1994-01-25 1995-08-09 Hoechst Aktiengesellschaft Alkyl carboxylique acide guanidines avec des groupes perfluoro-alkyls substituées par des groupes phényles, procédé de leur préparation, leur utilisation comme médicament ou agent diagnostique ainsi que médicament les contenant
EP0688766A1 (fr) * 1994-06-20 1995-12-27 Hoechst Aktiengesellschaft Guanidines d'acides alcénylcarboxyliques substituées par un groupe phényle portant des groupes perfluoroalcoyle, procédé pour leur préparation, leur utilisation comme médicament ou agent diagnostique, ainsi que médicament les contenant
EP0738712A1 (fr) * 1995-04-18 1996-10-23 Hoechst Aktiengesellschaft Indénoylguanidines substituées à activité antiarrythmique et cardioprotective
EP0744397A2 (fr) 1995-05-22 1996-11-27 Hoechst Aktiengesellschaft Guanidines d'acides alcénylcarboxyliques substituées par un groupe fluorophényle comme inhibiteurs de l'échange Na+/H+, leur procédé de préparation, leur utilisation comme médicament ou agent diagnostique ainsi que médicament les contenant
EP0755919A2 (fr) 1995-07-26 1997-01-29 Hoechst Aktiengesellschaft Guanidides d'acide cinnamique substitué, procédé de leur préparation, leur utilisation comme médicament cardiovasculaire ou agent diagnostique, ainsi que médicament les contenant
US5756535A (en) * 1996-02-15 1998-05-26 Hoechst Aktiengesellschaft Substituted thiophenylalkenylcarboxylic acid guanidines, processes for their preparation, their use as a medicament or diagnositc, and a medicament containing them
US5852046A (en) * 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
EP0901788A2 (fr) * 1997-08-28 1999-03-17 Hoechst Marion Roussel Deutschland GmbH Utilisation d'inhibiteurs de l'échange sodium-hydrogène pour la fabrication d'un médicament
US6005010A (en) * 1996-08-22 1999-12-21 Hoechst Aktiengesellschaft Phenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327561D0 (en) * 1983-10-14 1983-11-16 Ici Plc Contraceptive methods
US5358969A (en) * 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
US7041702B1 (en) * 1997-10-21 2006-05-09 Scion Pharmaceuticals, Inc. Pharmaceutically active compounds and methods of use
EP1814854B1 (fr) * 2004-10-29 2015-02-25 MUSC Foundation For Research Development Ceramides cationiques et leurs analogues, et leur utilisation pour la prevention ou le traitement du cancer
EP1814841A4 (fr) * 2004-10-29 2011-03-16 Musc Found For Res Dev Ceramides et ligands de signalisation de l'apoptose
CN101208297B (zh) * 2005-06-24 2013-04-24 拜伊特朗有限公司 抗病毒化合物和方法
KR101041428B1 (ko) 2008-10-13 2011-06-14 한국화학연구원 Ｎ1-2-티오펜-2-일에틸-ｎ2-치환된 바이구아나이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
EP2348839B1 (fr) 2008-11-06 2017-04-05 MUSC Foundation For Research Development Inhibiteurs lysosomotropes de céramidase acide
AU2009332952A1 (en) * 2008-12-30 2011-07-21 Musc Foundation For Research Development Sphingo-guanidines and their use as inhibitors of sphingosine kinase
GB0916163D0 (en) * 2009-09-15 2009-10-28 Shire Llc Prodrugs of guanfacine
KR101136045B1 (ko) 2009-11-16 2012-04-18 한국화학연구원 Ｎ1-(펜에틸)-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734904A (en) * 1956-02-14 Xcxnhxc-nh
US3349099A (en) * 1959-07-22 1967-10-24 Ciba Geigy Corp Aminoaryl-guanylhydrazones
US3632645A (en) * 1967-09-26 1972-01-04 A Wander Sa Dr Substituted phenylacetyl derivatives of guanidine o-alkylisoureas s-alkylisothioureas and p-nitrobenzylisothiourea
US4014876A (en) * 1969-11-12 1977-03-29 Shionogi & Co., Ltd. Isoxazole derivatives
US4340609A (en) * 1980-01-02 1982-07-20 William H. Rorer, Inc. Amidinourea derivative veterinary compositions for suppression of parasitemia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2740815A (en) * 1952-03-01 1956-04-03 Ruhrchemie Ag Production of amino carboxylic acid compounds
US3608087A (en) * 1968-06-21 1971-09-21 Merck & Co Inc Feed compositions
US3828078A (en) * 1971-04-19 1974-08-06 Merck & Co Inc 4-amino-3-(halo,nitro or trifluoromethyl)-5-trifluoromethyl benzenesulfonamides
DE2931735A1 (de) * 1979-08-04 1981-02-19 Beiersdorf Ag Neue substituierte phenylacetylguanidine und verfahren zu ihrer herstellung

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734904A (en) * 1956-02-14 Xcxnhxc-nh
US3349099A (en) * 1959-07-22 1967-10-24 Ciba Geigy Corp Aminoaryl-guanylhydrazones
US3632645A (en) * 1967-09-26 1972-01-04 A Wander Sa Dr Substituted phenylacetyl derivatives of guanidine o-alkylisoureas s-alkylisothioureas and p-nitrobenzylisothiourea
US4014876A (en) * 1969-11-12 1977-03-29 Shionogi & Co., Ltd. Isoxazole derivatives
US4340609A (en) * 1980-01-02 1982-07-20 William H. Rorer, Inc. Amidinourea derivative veterinary compositions for suppression of parasitemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0116639A4 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0612723A1 (fr) * 1993-02-20 1994-08-31 Hoechst Aktiengesellschaft Benzoylguanidines substituées, procédé de leur préparation, leur utilisation comme médicament, comme inhibiteurs de l'échange cellulaire de Na+/H+ ou comme agent diagnostique et médicament les contenant
US5852046A (en) * 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
EP0639573A1 (fr) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
EP0640587A1 (fr) * 1993-08-24 1995-03-01 Hoechst Aktiengesellschaft Guanidines diacyl substitués, procédé de leur préparation, leur utilisation comme médicament ou comme agent diagnostique ainsi que médicaments les contenant
US6436999B1 (en) 1993-08-24 2002-08-20 Hoechst Aktiengesellschaft Diacyl-substituted guanidines, a process for their preparation, their use as medicine or diagnostic aid, and medicine containing them
EP0921117A3 (fr) * 1993-08-24 1999-09-22 Hoechst Aktiengesellschaft Acylguanidines
EP0921117A2 (fr) * 1993-08-24 1999-06-09 Hoechst Aktiengesellschaft Acylguanidines
US6632840B1 (en) 1993-08-24 2003-10-14 Hoechst Aktiengesellschaft Monoacyl-substituted guanidines, a process for their preparation, their use as a medicament or diagnostic aid, and pharmaceutical compositions containing them
US5567734A (en) * 1994-01-25 1996-10-22 Hoechst Aktiengesellschaft Phenyl-substituted alkylcarboguanidides carrying perfluoroalkyl groups, a process for their preparation, their use as a medicament or a diagnostic agent, and a medicament containing them
EP0666252A1 (fr) * 1994-01-25 1995-08-09 Hoechst Aktiengesellschaft Alkyl carboxylique acide guanidines avec des groupes perfluoro-alkyls substituées par des groupes phényles, procédé de leur préparation, leur utilisation comme médicament ou agent diagnostique ainsi que médicament les contenant
EP0688766A1 (fr) * 1994-06-20 1995-12-27 Hoechst Aktiengesellschaft Guanidines d'acides alcénylcarboxyliques substituées par un groupe phényle portant des groupes perfluoroalcoyle, procédé pour leur préparation, leur utilisation comme médicament ou agent diagnostique, ainsi que médicament les contenant
US6025349A (en) * 1994-06-20 2000-02-15 Hoechst Aktiengesellschaft Phenyl.-substituted alkenylcarboguanidides carrying perfluoroalkyl groups, a process for their preparation, their use as a medicament or diagnostic agent, and also a medicament containing them
CN1062858C (zh) * 1994-06-20 2001-03-07 赫彻斯特股份公司 含氟的苯基取代链烯羧酰胍、制法、药用及其药品
US5733934A (en) * 1995-04-18 1998-03-31 Hoechst Aktiengesellschaft Antiarrythmic and cardioprotective substituted indenoylguanidines
EP0738712A1 (fr) * 1995-04-18 1996-10-23 Hoechst Aktiengesellschaft Indénoylguanidines substituées à activité antiarrythmique et cardioprotective
AU701493B2 (en) * 1995-05-22 1999-01-28 Hoechst Aktiengesellschaft Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
EP0744397A2 (fr) 1995-05-22 1996-11-27 Hoechst Aktiengesellschaft Guanidines d'acides alcénylcarboxyliques substituées par un groupe fluorophényle comme inhibiteurs de l'échange Na+/H+, leur procédé de préparation, leur utilisation comme médicament ou agent diagnostique ainsi que médicament les contenant
US6504057B2 (en) 1995-05-22 2003-01-07 Hoechst Aktiengesellschaft Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
EP0755919A2 (fr) 1995-07-26 1997-01-29 Hoechst Aktiengesellschaft Guanidides d'acide cinnamique substitué, procédé de leur préparation, leur utilisation comme médicament cardiovasculaire ou agent diagnostique, ainsi que médicament les contenant
US5883133A (en) * 1995-07-26 1999-03-16 Hoechst Aktiengesellschaft Substituted cinnamic acid guanidides, a process for their preparation, their use as medicaments or diagnostic agents and medicaments comprising them
US5756535A (en) * 1996-02-15 1998-05-26 Hoechst Aktiengesellschaft Substituted thiophenylalkenylcarboxylic acid guanidines, processes for their preparation, their use as a medicament or diagnositc, and a medicament containing them
CN1065861C (zh) * 1996-08-22 2001-05-16 赫彻斯特股份公司 苯基取代的链烯基羧酸胍、其制备方法、其作为药物或诊断剂的应用以及含有它的药
US6005010A (en) * 1996-08-22 1999-12-21 Hoechst Aktiengesellschaft Phenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
AU738599B2 (en) * 1997-08-28 2001-09-20 Sanofi-Aventis Deutschland Gmbh Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa
US6114393A (en) * 1997-08-28 2000-09-05 Hoechst Marion Roussel Deutschland Gmbh Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa
EP0901788A2 (fr) * 1997-08-28 1999-03-17 Hoechst Marion Roussel Deutschland GmbH Utilisation d'inhibiteurs de l'échange sodium-hydrogène pour la fabrication d'un médicament
EP0901788A3 (fr) * 1997-08-28 2004-01-02 Aventis Pharma Deutschland GmbH Utilisation d'inhibiteurs de l'échange sodium-hydrogène pour la fabrication d'un médicament
CZ296815B6 (cs) * 1997-08-28 2006-06-14 Sanofi - Aventis Deutschland GmbH Lécivo proti nemocím zpusobeným prvoky
KR100567144B1 (ko) * 1997-08-28 2006-11-30 사노피-아벤티스 도이칠란트 게엠베하 나트륨-수소 교환체 억제제를 포함하는, 열대말라리아 질환 치료용 약제학적 조성물

Also Published As

Publication number Publication date
EP0116639A4 (fr) 1985-09-25
AU557648B2 (en) 1986-12-24
AU2035183A (en) 1984-03-29
EP0116639A1 (fr) 1984-08-29
JPS59501717A (ja) 1984-10-11
US4544670A (en) 1985-10-01

Similar Documents

Publication Publication Date Title
US4544670A (en) Method of treating coccidiosis with acyl guanidines
DE2734070C2 (de) Aminoalkylfuranderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU617139B2 (en) New phenylethanolamines
US4556662A (en) Bispidine derivatives and antiarrhythmic compositions
US4112234A (en) Imidazolylmethylthioethyl alkynyl guanidines
US3639477A (en) Novel propoxyguanidine compounds and means of producing the same
EP0059356B1 (fr) Amino-3-sydnone imines substitués, procédé pour leur préparation et leur application
PL135749B1 (en) Method of obtaining novel imidazolilophenylamidines
GB2243833A (en) 2-substituted 4-amino-5-chloro-n-[2-(diethylamino)ethyl]-benzamides
IL30782A (en) Amino guanidines
US4046753A (en) Substituted 2-phenylhydrazino and 2-phenylazo thiazolines
JPS6261960A (ja) 不可逆性ド−パミン−β−ヒドロキシラ−ゼ抑制剤
DE3035688C2 (fr)
US3666860A (en) Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents
US4006233A (en) N-(pyrimidinyl)-tricyclo[3(or 4).2.2.02,4(or 5) ]-non (or dec)ene-dicarboximides
US5244895A (en) Anti-ulcer agent
US3740434A (en) Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents
US3842174A (en) Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents
AU7539481A (en) Heterocyclic amidino substituted ureas and their pharmaceutical uses
EP0025109A2 (fr) Dérivés de 1-benzoxépin-5(2H)-ones et leurs sels, et procédés pour leur préparation
EP0206364A2 (fr) Amidino-urées hétérocycliques
AU597600B2 (en) Dopamine-beta-hydroxylase inhibitors
EP0055145B1 (fr) Dérivés de l'acide (aminométhyl)-4 cyclohexane-carboxylique-1
US3313687A (en) Appetite-suppressing and weight reducing composition
US3786050A (en) Diphenyl sulfones

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU JP

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB LU NL SE

CR1 Correction of entry in section i

Free format text: IN 07/84 REPLACE BEF.THE EXPIR.OF THE TIME LIMIT FOR AMENDING THE CLAIMS A.TO BE REPUBL.IN THE EVENT OF THE RECEIPT OF AMENDM.BY WITH AMEND.CLAIMS

WWE Wipo information: entry into national phase

Ref document number: 1983903029

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1983903029

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1983903029

Country of ref document: EP